HAYWARD, Calif., May 13 Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it has received the Provectus Award presented by MDB Capital Group at the first annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property (IP).
"We are honored to have our technological innovation recognized by MDB Capital Group. Solta Medical has invested more than 14 years developing, validating and creating the leading IP portfolio in the aesthetic energy device industry," said Stephen J. Fanning, Chairman of the Board, President and Chief Executive Officer. "We will continue to invest in the scientific research needed to develop new, innovative aesthetic procedures." Solta Medical currently holds more than 110 patents in the U.S. and abroad as well as over 170 additional patents pending.
The inaugural Bright Lights Conference showcased 50 of the most innovative public companies ranked in the 90th percentile for technology leadership from more than 1,600 small cap companies with U.S. patents. The companies were scored, ranked and analyzed using PatentVest, MDB's proprietary IP business intelligence database, taking into consideration PatentVest Tech Score, 3 Year Patent Application CAGR, number of patents granted, patent applications on file and Application Conversion Ratio. The companies also were judged on significance of technology within an industry, product innovation in terms of novel or disruptive technology, unique competitive advantages, stage of technology development and estimated time to market.
PatentVest ranks Solta Medical in the top 5% in each of the quantitative metrics across the entire health care sector, and number one in IP critical mass, IP impact, IP strength and IP growth rate.
According to PatentVest, "Among public companies in the aesthetic equipment device (AED) industry, our IP metrics found that Solta Medical is innovating faster and generating game-changing IP."
"Intellectual property is no longer an intangible asset class," said Christopher Marlett, Chairman and CEO of MDB Capital Group. "MDB Capital built PatentVest to help investors easily assign a tangible value to patents, and we've proven that market leading IP is predictive of superior business performance. Companies like Solta Medical typify the market leading IP presented at our Bright Lights Conference. We are proud to recognize its achievements with the Provectus Award, which recognizes strength of IP process leadership."
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's three premier brands: Thermage®, Fraxel® and Isolaz®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2009, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
SOURCE Solta Medical, Inc.